Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | PYCR1 | P32322 | 7/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31612505 | 0.94 | KDM4E (0.64) | KDM4EALDH1A1PYCR1MAOBSIGMAR1 | |
| SCHEMBL7132148 | 0.90 | MAPT (0.53) | KDM4EALDH1A1PYCR1MAOBSIGMAR1 | |
| SCHEMBL1241978 | 0.88 | KDM4E (0.70) | KDM4EALDH1A1PYCR1MAOBSIGMAR1 | |
| SCHEMBL8254170 | 0.84 | KDM4E (0.50) | KDM4EALDH1A1PYCR1MAOBSIGMAR1 | |
| SCHEMBL7128368 | 0.84 | SIGMAR1 (0.55) | KDM4EALDH1A1PYCR1MAOBSIGMAR1 | |
| SCHEMBL12082322 | 0.82 | PYCR1 (0.52) | KDM4EALDH1A1PYCR1MAOBSIGMAR1 | |
| SCHEMBL8724611 | 0.82 | SIGMAR1 (0.58) | KDM4EALDH1A1MAOBSIGMAR1TMEM97 | |
| SCHEMBL8722902 | 0.82 | SIGMAR1 (0.58) | KDM4EALDH1A1MAOBSIGMAR1TMEM97 | |
| SCHEMBL7764937 | 0.82 | SIGMAR1 (0.58) | KDM4EALDH1A1MAOBSIGMAR1TMEM97 | |
| SCHEMBL7764359 | 0.82 | SIGMAR1 (0.58) | KDM4EALDH1A1MAOBSIGMAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2151447-A1 | LINCOMYCIN DERIVATIVES AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Meiji Seika Kaisha Ltd. (JP) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | LAS1L, LCLAT1, LYPLA1 | KDM4E 3818/4885ALDH1A1 3224/4885PYCR1 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.